Ignite Creation Date:
2025-12-24 @ 7:51 PM
Ignite Modification Date:
2025-12-25 @ 5:27 PM
Study NCT ID:
NCT01123304
Status:
TERMINATED
Last Update Posted:
2014-07-17
First Post:
2010-05-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
Sponsor:
Morphotek
Organization:
Study Overview
Official Title:
A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma
Status:
TERMINATED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This study has been terminated due to lack of availability of investigational product.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: